{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T12:40:05Z","timestamp":1744029605359,"version":"3.40.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,7]]},"DOI":"10.7759\/cureus.81824","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:58:58Z","timestamp":1744027138000},"source":"Crossref","is-referenced-by-count":0,"title":["New Therapies for the Management of Chronic Kidney Disease"],"prefix":"10.7759","author":[{"given":"Andrew M","family":"Treihaft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish A","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaedrea A","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02542-4","article-title":"Blocking aldosterone or its receptor\u2014what is the difference?","volume":"403","author":"Agarwal R","year":"2024","unstructured":"Agarwal R. Blocking aldosterone or its receptor\u2014what is the difference?. Lancet. 2024, 403:330-2. 10.1016\/s0140-6736(23)02542-4","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142024","volume":"47","author":"ElSayed NA","year":"2024","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, et al.. 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024, 47:S219-30. 10.2337\/dc24-S011","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12531","article-title":"Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement","volume":"326","author":"Davidson KW","year":"2021","unstructured":"Davidson KW, Barry MJ, Mangione CM, et al.. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA. 2021, 326:736-43. 10.1001\/jama.2021.12531","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen TK","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019, 322:1294-304. 10.1001\/jama.2019.14745","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051335","article-title":"Chronic renal failure and cardiovascular disease: a comprehensive appraisal","volume":"11","author":"Skalsky K","year":"2022","unstructured":"Skalsky K, Shiyovich A, Steinmetz T, Kornowski R. Chronic renal failure and cardiovascular disease: a comprehensive appraisal. J Clin Med. 2022, 11:1335. 10.3390\/jcm11051335","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer IH","year":"2020","unstructured":"de Boer IH, Caramori ML, Chan JC, et al.. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020, 98:S1-115. 10.1016\/j.kint.2020.06.019","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022, 45:3075-90. 10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07820719","article-title":"Preserving kidney function instead of replacing it","volume":"15","author":"Kliger AS","year":"2020","unstructured":"Kliger AS, Brosius FC, Quaggin S, et al.. Preserving kidney function instead of replacing it. Clin J Am Soc Nephrol. 2020, 15:129-31. 10.2215\/CJN.07820719","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref9","article-title":"Chronic kidney disease","author":"Vaidya SR","year":"2024","unstructured":"Vaidya SR, Aeddula NR. Chronic kidney disease. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000838","article-title":"Aldosterone synthase inhibitor BI 690517: specificity for mineralocorticoid receptor","volume":"0","author":"Treihaft AM","year":"2025","unstructured":"Treihaft AM, Parikh MA, Jackson KA, Frishman WH, Peterson SJ. Aldosterone synthase inhibitor BI 690517: specificity for mineralocorticoid receptor. Cardiol Rev. 2025, 0:0. 10.1097\/CRD.0000000000000838","journal-title":"Cardiol Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac331","article-title":"The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes","volume":"38","author":"Agarwal R","year":"2023","unstructured":"Agarwal R, Fouque D. The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes. Nephrol Dial Transplant. 2023, 38:253-7. 10.1093\/ndt\/gfac331","journal-title":"Nephrol Dial Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0005","article-title":"SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review","volume":"12","author":"Thomas MC","year":"2023","unstructured":"Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023, 12:e230005. 10.1530\/EC-23-0005","journal-title":"Endocr Connect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen BL","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJ, et al.. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019, 7:845-54. 10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-00913-4","article-title":"Aldosterone breakthrough from a pharmacological perspective","volume":"45","author":"Mogi M","year":"2022","unstructured":"Mogi M. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res. 2022, 45:967-75. 10.1038\/s41440-022-00913-4","journal-title":"Hypertens Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic RZ","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017, 12:2032-45. 10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","author":"Judge PK","year":"2024","unstructured":"Judge PK, Tuttle KR, Staplin N, et al.. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol Dial Transplant. 2024, fae263. 10.1093\/ndt\/gfae263","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases","volume":"29","author":"Namsolleck P","year":"2014","unstructured":"Namsolleck P, Unger T. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant. 2014, 29:i62-8. 10.1093\/ndt\/gft402","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36184","article-title":"Aldosterone synthase inhibitors and dietary interventions: a combined novel approach for prevention and treatment of cardiovascular disease","volume":"15","author":"Awosika A","year":"2023","unstructured":"Awosika A, Khan A, Adabanya U, Omole AE, Millis RM. Aldosterone synthase inhibitors and dietary interventions: a combined novel approach for prevention and treatment of cardiovascular disease. Cureus. 2023, 15:e36184. 10.7759\/cureus.36184","journal-title":"Cureus"},{"key":"ref19","article-title":"Using ACE inhibitors and ARBs in advanced chronic kidney disease does not worsen, and may improve, renal outcomes","volume":"107","author":"Ebell MH","year":"2023","unstructured":"Ebell MH. Using ACE inhibitors and ARBs in advanced chronic kidney disease does not worsen, and may improve, renal outcomes. Am Fam Physician. 2023, 107:0.","journal-title":"Am Fam Physician"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1097\/SMJ.0b013e3181e1e2da","article-title":"Angiotensin receptor blockers for management of hypertension","volume":"103","author":"Catanzaro DF","year":"2010","unstructured":"Catanzaro DF, Frishman WH. Angiotensin receptor blockers for management of hypertension. South Med J. 2010, 103:669-73.","journal-title":"South Med J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil S","year":"2015","unstructured":"Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015, 116:1074-95. 10.1161\/CIRCRESAHA.116.303603","journal-title":"Circ Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03427-0","article-title":"Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors","volume":"19","author":"De Nicola L","year":"2024","unstructured":"De Nicola L, Ferraro PM, Montagnani A, Pontremoli R, Dentali F, Sesti G. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors. Intern Emerg Med. 2024, 19:295-306. 10.1007\/s11739-023-03427-0","journal-title":"Intern Emerg Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:323-34. 10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas S","year":"2021","unstructured":"Zoungas S, de Boer IH. SGLT2 inhibitors in diabetic kidney disease. Clin J Am Soc Nephrol. 2021, 16:631-3. 10.2215\/CJN.18881220","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173955","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes","volume":"10","author":"Rojano Toimil A","year":"2021","unstructured":"Rojano Toimil A, Ciudin A. GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes. J Clin Med. 2021, 10:3955. 10.3390\/jcm10173955","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0372-3","article-title":"Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists","volume":"75","author":"Glicklich D","year":"2015","unstructured":"Glicklich D, Frishman WH. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. Drug. 2015, 75:473-85. 10.1007\/s40265-015-0372-3","journal-title":"Drug"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner C","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005, 353:238-48. 10.1056\/NEJMoa043545","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m BC","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, et al.. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009, 360:1395-407. 10.1056\/NEJMoa0810177","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-11-4-235","article-title":"Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure","volume":"11","author":"Sica DA","year":"2015","unstructured":"Sica DA. Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist Debakey Cardiovasc J. 2015, 11:235-9. 10.14797\/mdcj-11-4-235","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S315359","article-title":"Clinical utility of osilodrostat in Cushing\u2019s disease: review of currently available literature","volume":"17","author":"Perosevic M","year":"2023","unstructured":"Perosevic M, Tritos NA. Clinical utility of osilodrostat in Cushing\u2019s disease: review of currently available literature. Drug Des Devel Ther. 2023, 17:1303-12. 10.2147\/DDDT.S315359","journal-title":"Drug Des Devel Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000665","article-title":"Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors","volume":"0","author":"Feldman JM","year":"2024","unstructured":"Feldman JM, Frishman WH, Aronow WS. Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors. Cardiol Rev. 2024, 0:0. 10.1097\/CRD.0000000000000665","journal-title":"Cardiol Rev"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000595","article-title":"Baxdrostat: an aldosterone synthase inhibitor for the treatment of systemic hypertension","volume":"0","author":"Dey S","year":"2023","unstructured":"Dey S, Frishman WH, Aronow WS. Baxdrostat: an aldosterone synthase inhibitor for the treatment of systemic hypertension. Cardiol Rev. 2023, 0:0. 10.1097\/CRD.0000000000000595","journal-title":"Cardiol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/347957-new-therapies-for-the-management-of-chronic-kidney-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:59:15Z","timestamp":1744027155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/347957-new-therapies-for-the-management-of-chronic-kidney-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.81824","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}